Two Sigma Investments LP reduced its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 53.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 17,268 shares of the medical equipment provider’s stock after selling 19,800 shares during the period. Two Sigma Investments LP owned approximately 0.05% of AxoGen worth $489,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of AXGN. Guggenheim Capital LLC purchased a new position in AxoGen during the 4th quarter worth $228,000. OxFORD Asset Management LLP purchased a new position in AxoGen during the 3rd quarter worth $270,000. Teacher Retirement System of Texas purchased a new position in AxoGen during the 4th quarter worth $271,000. Aperio Group LLC purchased a new position in AxoGen during the 4th quarter worth $412,000. Finally, Neuberger Berman Group LLC grew its position in AxoGen by 133.3% during the 3rd quarter. Neuberger Berman Group LLC now owns 28,000 shares of the medical equipment provider’s stock worth $542,000 after purchasing an additional 16,000 shares during the last quarter. 67.84% of the stock is currently owned by institutional investors.
AXGN stock opened at $37.95 on Friday. AxoGen, Inc has a one year low of $11.30 and a one year high of $40.95. The firm has a market capitalization of $1,327.11, a PE ratio of -122.42 and a beta of 0.01. The company has a quick ratio of 3.53, a current ratio of 4.07 and a debt-to-equity ratio of 0.79.
AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. AxoGen had a negative net margin of 17.29% and a negative return on equity of 70.63%. The company had revenue of $16.97 million during the quarter, compared to analysts’ expectations of $16.38 million. During the same quarter last year, the business earned ($0.10) EPS. The business’s revenue was up 48.7% on a year-over-year basis. research analysts expect that AxoGen, Inc will post -0.3 EPS for the current year.
In other news, Director Jamie Mark Grooms sold 63,395 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $27.67, for a total value of $1,754,139.65. Following the completion of the sale, the director now owns 5,827 shares in the company, valued at approximately $161,233.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 169,407 shares of company stock valued at $4,593,013 in the last 90 days. Company insiders own 7.86% of the company’s stock.
Several research analysts have issued reports on the stock. Lake Street Capital set a $38.00 price objective on shares of AxoGen and gave the stock a “buy” rating in a research report on Friday, March 2nd. JMP Securities raised their price objective on shares of AxoGen from $27.00 to $34.00 and gave the stock a “market outperform” rating in a research report on Thursday, March 1st. Cantor Fitzgerald set a $37.00 price objective on shares of AxoGen and gave the stock a “buy” rating in a research report on Monday, January 8th. William Blair assumed coverage on shares of AxoGen in a research report on Monday, February 5th. They set an “outperform” rating on the stock. Finally, BidaskClub downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 11th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $33.14.
WARNING: “Two Sigma Investments LP Lowers Holdings in AxoGen, Inc (AXGN)” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2018/04/15/two-sigma-investments-lp-lowers-holdings-in-axogen-inc-axgn.html.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.